OpenNashEarnings

Cardinal Health (CAH) · Health Care

Cardinal Health Q4 FY2026 earnings: summary, key numbers & outlook

Results filed 11 Aug 2026 · Quarter ended 30 Jun 2026

Slides (31 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Cardinal Health is shifting growth toward specialty physician platforms and higher-margin home, logistics and nuclear businesses while the medical products turnaround gains traction, with a tuck-in acquisition added in fiscal 2027.

Cardinal's pharma distribution business grew on brand and specialty sales from existing customers, and the company renewed its wholesaler contract with Kroger. Its Other businesses (Nuclear and Precision Health Solutions, OptiFreight Logistics and at-Home Solutions) grew across all three units. Medical products revenue fell on lower distribution volumes, while Cardinal Health Brand kept growing.

Management plans to deepen its role supporting community specialty physicians, expand the higher-margin growth businesses, and keep executing the medical products improvement plan. Two tuck-in deals (Strive Medical and AdaptHealth's Diabetes Health business) and a new Indianapolis distribution center support that. The main tension is that medical products profit depends on tariffs and the plan, and drug pricing rules, generic deflation and contract renewals remain risks.

Slides & documents

Open the slide deck (PDF, 31 pages) ↗

Cardinal Health Q4 FY2026 slide deck, page 1Cardinal Health Q4 FY2026 slide deck, page 2Cardinal Health Q4 FY2026 slide deck, page 3Cardinal Health Q4 FY2026 slide deck, page 4Cardinal Health Q4 FY2026 slide deck, page 5Cardinal Health Q4 FY2026 slide deck, page 6

Showing the first 6 of 31 pages.

From Cardinal Health investor relations

SEC filing

Key numbers

Q4 revenue
$63.7 billion

up 6% from the fourth quarter of fiscal year 2025

Q4 diluted EPS · GAAP
$1.70

up 70%

Q4 diluted EPS · non-GAAP
$2.91

up 40%

Q4 operating earnings · GAAP
$729 million

up 70%

Q4 non-GAAP operating earnings · non-GAAP
$935 million

up 30%

Q4 net earnings attributable to Cardinal Health · GAAP
$398.0M

67% from a year ago

Fiscal 2026 operating cash flow · GAAP
$5.2 billion

Fiscal 2026 adjusted free cash flow · non-GAAP
$5.0 billion

Segment or metricValueChange
Pharmaceutical and Specialty Solutions revenue$58.8 billionup 6%
Pharmaceutical and Specialty Solutions segment profit$645 millionup 21%
Global Medical Products and Distribution revenue$3.1 billiondown 2%
Global Medical Products and Distribution segment profit$150 millionN.M.
Other revenue$1.7 billionup 7%
Other segment profit$183 millionup 14%
Where each number comes from
  • Q4 revenue: “today reported fourth quarter fiscal year 2026 revenues of $63.7 billion, an increase of 6% from the fourth quarter of fiscal year 2025.”
  • Q4 diluted EPS: “Fourth quarter GAAP operating earnings increased 70% to $729 million and GAAP diluted earnings per share (EPS) increased 70% to $1.70.”
  • Q4 diluted EPS: “Non-GAAP diluted EPS increased 40% to $2.91, reflecting the increase in non-GAAP earnings, including the recognition of a one-time net operating profit impact”
  • Q4 operating earnings: “Fourth quarter GAAP operating earnings increased 70% to $729 million and GAAP diluted earnings per share (EPS) increased 70% to $1.70.”
  • Q4 non-GAAP operating earnings: “Non-GAAP operating earnings increased 30% to $935 million.”
  • Q4 net earnings attributable to Cardinal Health: “Net earnings attributable to Cardinal Health, Inc. | $398 million | $239 million | 67% | $1.7 billion | $1.6 billion | 10%”
  • Fiscal 2026 operating cash flow: “Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion”
  • Fiscal 2026 adjusted free cash flow: “Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion”
  • Pharmaceutical and Specialty Solutions revenue: “Fourth-quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 6% to $58.8 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.”
  • Pharmaceutical and Specialty Solutions segment profit: “Pharmaceutical and Specialty Solutions segment profit increased 21% to $645 million in the fourth quarter, primarily driven by contributions from brand and specialty products”
  • Global Medical Products and Distribution revenue: “Fourth-quarter revenue for the Global Medical Products and Distribution segment decreased 2% from the prior year to $3.1 billion.”
  • Global Medical Products and Distribution segment profit: “Global Medical Products and Distribution segment profit increased to $150 million in the fourth quarter, primarily driven by IEEPA tariff refunds.”
  • Other revenue: “Fourth-quarter revenue for Other increased 7% to $1.7 billion, driven by growth across the three operating segments”
  • Other segment profit: “Other segment profit increased 14% to $183 million in the fourth quarter, driven by growth in OptiFreight Logistics and at-Home Solutions.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

XBRL figures for this quarter arrive with the 10-Q or 10-K; the numbers above are from the press release.

Outlook

MetricPeriodOutlook
Non-GAAP diluted EPSfiscal year 2027$12.40 to $12.60
Pharmaceutical and Specialty Solutions revenue growthfiscal year 20273% to 5% growth
Pharmaceutical and Specialty Solutions segment profit growthfiscal year 20278% to 11% growth
Global Medical Products and Distribution revenue growthfiscal year 20272% to 4% growth
Global Medical Products and Distribution segment profitfiscal year 2027$200 million to $220 million
Other segment revenue growthfiscal year 202711% to 13% growth
Other segment profit growthfiscal year 202715% to 18% growth
Non-GAAP effective tax ratefiscal year 202719.0% to 20.0%
Capital expendituresfiscal year 2027~$700 million
Non-GAAP adjusted free cash flowfiscal year 2027$3.5 billion to $4.0 billion

Key takeaways

  1. Specialty physician platforms anchor pharma growth strategy

    Cardinal is positioning itself to support community-based physicians through MSO platforms, data and technology, scaled contracting and specialty distribution. Recent practice acquisitions (Integrated Oncology Network, GI Alliance, Urology America, Solaris Health) deepen this model.

  2. Higher-margin Other businesses are the growth engine

    Nuclear and Precision Health Solutions, OptiFreight Logistics and at-Home Solutions grew across all three units, and management expects 11% to 13% revenue growth next year. Cardinal is investing in PET and Theranostics capacity and launched an outbound pharmacy shipping solution.

  3. Two tuck-in acquisitions extend home-care footprint

    Cardinal completed the Strive Medical acquisition and announced the Diabetes Health business of AdaptHealth, both reflected in fiscal 2027 guidance. They build on care shifting to more cost-effective, comfortable settings.

  4. Medical products turnaround is progressing, tariff-dependent

    U.S. Cardinal Health Brand revenue grew at least mid single digits for six consecutive quarters, with simplified manufacturing and more domestic production. Even so, quarterly segment profit excluding IEEPA refunds fell from $70 million to $50 million.

  5. Kroger renewal and new automated center add capacity

    Cardinal announced a long-term renewal of its wholesaler distribution contract with Kroger. A new Indianapolis distribution center with advanced robotics and automation is set to open in 2027.

Charts

Revenue$67.5B+5.5% y/yQ1 FY27
Q4 FY24: $59.9B (worked out from the annual figure)Q4 24$59.9BQ1 FY25: $52.3BQ1 25$52.3BQ2 FY25: $55.3BQ2 25$55.3BQ3 FY25: $54.9BQ3 25$54.9BQ4 FY25: $60.2B (worked out from the annual figure)Q4 25$60.2BQ1 FY26: $64.0BQ1 26$64.0BQ2 FY26: $65.6BQ2 26$65.6BQ1 FY27: $67.5BQ1 27$67.5B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$59.9B *
Q1 FY25$52.3B
Q2 FY25$55.3B
Q3 FY25$54.9B
Q4 FY25$60.2B *
Q1 FY26$64.0B
Q2 FY26$65.6B
Q1 FY27$67.5B
Diluted EPS (GAAP)$2.38+26.6% y/yQ1 FY27
Q1 FY25: $1.70Q1 25$1.70Q1 FY26: $1.88Q1 26$1.88Q1 FY27: $2.38Q1 27$2.38
Data
Q1 FY25$1.70
Q1 FY26$1.88
Q1 FY27$2.38

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.1%+0.1 pts y/yQ1 FY27
Q4 FY24: 0.7%Q4 240.7%Q1 FY25: 1.1%Q1 251.1%Q2 FY25: 1.0%Q2 251.0%Q3 FY25: 1.3%Q3 251.3%Q4 FY25: 0.7%Q4 250.7%Q1 FY26: 1.0%Q1 261.0%Q2 FY26: 1.1%Q2 261.1%Q1 FY27: 1.1%Q1 271.1%
Data
Q4 FY240.7%
Q1 FY251.1%
Q2 FY251.0%
Q3 FY251.3%
Q4 FY250.7%
Q1 FY261.0%
Q2 FY261.1%
Q1 FY271.1%
Free cash flow$1.2B+43.5% y/yQ1 FY27
Q4 FY24: $1.9BQ4 24$1.9BQ1 FY25: -$1.7BQ1 25-$1.7BQ2 FY25: -$495.0MQ2 25-$495.0MQ3 FY25: $2.8BQ3 25$2.8BQ4 FY25: $1.3BQ4 25$1.3BQ1 FY26: $865.0MQ1 26$865.0MQ2 FY26: $555.0MQ2 26$555.0MQ1 FY27: $1.2BQ1 27$1.2B
Data
Q4 FY24$1.9B
Q1 FY25-$1.7B
Q2 FY25-$495.0M
Q3 FY25$2.8B
Q4 FY25$1.3B
Q1 FY26$865.0M
Q2 FY26$555.0M
Q1 FY27$1.2B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is Cardinal Health's main strategic focus for fiscal 2027?

Its priorities are simplification, expanding in specialty within Pharmaceutical and Specialty Solutions, executing the GMPD Improvement Plan, and accelerating the higher-margin Other businesses.

How is Cardinal supporting community physicians?

It offers MSO platforms in oncology and other specialties, data and technology solutions such as analytics and real-world evidence, plus broad distribution, scaled contracting and GPO offerings.

Which acquisitions does Cardinal's fiscal 2027 outlook include?

The outlook reflects the completed tuck-in acquisition of Strive Medical and the announced tuck-in acquisition of the Diabetes Health business of AdaptHealth.

How is the medical products business doing?

Cardinal Health Brand U.S. revenue grew at least mid single digits for six consecutive quarters, but distribution volumes fell and quarterly segment profit excluding tariff refunds declined.

What capacity investments is Cardinal making?

It plans about $700 million of capital spending covering automation, new distribution centers, nuclear capacity and MSO platform technology, including an Indianapolis distribution center opening in 2027.